
    
      A phase 2, multicenter, multi-cohort, open-label study of pomalidomide in combination with
      low-dose dexamethasone or pomalidomide in combination with low-dose dexamethasone and
      daratumumab in subjects with relapsed or refractory multiple myeloma following lenalidomide
      based therapy in the first or second line setting.

      This trial will assess, Overall Response Rate (ORR), Overall Survival (OS), Progression-Free
      Survival (PFS), Duration of Response (DoR), Time to Response (TTR), Time to Progression(TTP)
      and safety.
    
  